Phase 1 study of AVN-211 for schizophrenia

Avineuro Pharmaceuticals announced an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of schizophrenia.  The results of Phase I studies are expected to be available in April 2009.

For more information visit